Asia Pacific Biologics Contract Manufacturing Market Size & Outlook
Related Markets
Asia Pacific biologics contract manufacturing market highlights
- The Asia Pacific biologics contract manufacturing market generated a revenue of USD 9,318.6 million in 2024.
- The market is expected to grow at a CAGR of 10.9% from 2025 to 2030.
- In terms of segment, monoclonal antibodies (mabs) was the largest revenue generating product in 2024.
- Vaccines is the most lucrative product segment registering the fastest growth during the forecast period.
- Country-wise, China is expected to register the highest CAGR from 2025 to 2030.
Asia Pacific data book summary
| Market revenue in 2024 | USD 9,318.6 million |
| Market revenue in 2030 | USD 17,435.5 million |
| Growth rate | 10.9% (CAGR from 2025 to 2030) |
| Largest segment | Monoclonal antibodies (mabs) |
| Fastest growing segment | Vaccines |
| Historical data covered | 2018 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Vaccines, Monoclonal Antibodies (mAbs), Recombinant Protein, Antisense, RNAi, & Molecular Therapy |
| Key market players worldwide | WuXi Biologics (Cayman) Inc, FUJIFILM Holdings Corp, Boehringer Ingelheim, Lonza Group Ltd, AbbVie Inc, Catalent Inc, Merck & Co Inc, Thermo Fisher Scientific Inc, Eurofins Scientific SE, Abzena, Samsung BioLogics |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 29.2% of the global biologics contract manufacturing market in 2024.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 17,435.5 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Biologics Contract Manufacturing Market Scope
Biologics Contract Manufacturing Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Abzena | View profile | 501-1000 | San Diego, California, United States, North America | http://abzena.com/ |
| Samsung BioLogics | View profile | 1001-5000 | Incheon, Inch'on-jikhalsi, South Korea, Asia | https://www.samsungbiologics.com/ |
| Catalent Inc | View profile | 17219 | 14 Schoolhouse Road, Somerset, NJ, United States, 08873 | https://www.catalent.com |
| WuXi Biologics (Cayman) Inc | View profile | 12740 | No. 108, Meiliang Road, Mashan Binhu District, Wuxi, China, People's Republic of, 214092 | https://www.wuxibiologics.com |
| Boehringer Ingelheim | View profile | 10001+ | Ingelheim Am Rhein, Rheinland-Pfalz, Germany, Europe | https://www.boehringer-ingelheim.com/ |
| Merck & Co Inc | View profile | 72000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | https://www.merck.com |
| Eurofins Scientific SE | View profile | 61798 | 23 Val Fleuri, Luxembourg, Luxembourg, L-1526 | https://www.eurofins.com |
| Thermo Fisher Scientific Inc | View profile | 122000 | 168 Third Avenue, Waltham, MA, United States, 02451 | https://www.thermofisher.com |
| FUJIFILM Holdings Corp | View profile | 83784 | 7-3, Akasaka 9-chome, Minato-ku, Tokyo, Japan, 107-0052 | http://www.fujifilmholdings.com |
| Lonza Group Ltd | View profile | 18000 | Muenchensteinerstrasse 38, Basel, Switzerland, CH-4002 | https://www.lonza.com |
| AbbVie Inc | View profile | 50000 | 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 | http://www.abbvieinvestor.com |
Asia Pacific biologics contract manufacturing market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biologics contract manufacturing market will help companies and investors design strategic landscapes.
Monoclonal antibodies (mabs) was the largest segment with a revenue share of 58.1% in 2024. Horizon Databook has segmented the Asia Pacific biologics contract manufacturing market based on vaccines, monoclonal antibodies (mabs), recombinant protein, antisense, rnai, & molecular therapy covering the revenue growth of each sub-segment from 2018 to 2030.
- Asia Pacific Biologics Contract Manufacturing Product Outlook (Revenue, USD Million, 2018-2030)
- Monoclonal Antibodies (mAbs)
- Recombinant Protein
- Vaccines
- Antisense, RNAi, & Molecular Therapy
- Others
- Asia Pacific Biologics Contract Manufacturing Indication Outlook (Revenue, USD Million, 2018-2030)
- Oncology
- Autoimmune Diseases
- Infectious Diseases
- Metabolic Diseases
- Neurology
- Cardiovascular Disorders (CVDs)
- Others
Reasons to subscribe to Asia Pacific biologics contract manufacturing market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Asia Pacific biologics contract manufacturing market databook
-
Our clientele includes a mix of biologics contract manufacturing market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific biologics contract manufacturing market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific biologics contract manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Asia Pacific biologics contract manufacturing market size, by country, 2018-2030 (US$M)
Asia Pacific Biologics Contract Manufacturing Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
